Sponsor: ECOG-ACRIN Cancer Research Group
Sponsor Study ID: EA2174
Study Title: A Phase II/III Study of Peri operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
CTO #: 103646
NCT Number: NCT03604991
Phase: II/III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Esophagus
Study Objectives: This phase II/III trial studies the usefulness of treatment with nivolumab and ipilimumab in addition to standard of care chemotherapy and radiation therapy in patients with esophageal and gastroesophageal junction adenocarcinoma who are undergoing surgery.